Literature DB >> 23450321

Echocardiographic and hemodynamic predictors of mortality in idiopathic pulmonary fibrosis.

Belinda N Rivera-Lebron1, Paul R Forfia2, Maryl Kreider1, James C Lee1, John H Holmes3, Steven M Kawut4.   

Abstract

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) can lead to the development of pulmonary hypertension, which is associated with an increased risk of death. In pulmonary arterial hypertension, survival is directly related to the capacity of the right ventricle to adapt to elevated pulmonary vascular load. The relative importance of right ventricular function in IPF is not well understood. Our objective was to evaluate right ventricular echocardiographic and hemodynamic predictors of mortality in a cohort of patients with IPF referred for lung transplant evaluation.
METHODS: We performed a retrospective cohort study of 135 patients who met 2011 American Thoracic Society/European Respiratory Society criteria for IPF and who were evaluated for lung transplantation at the Hospital of the University of Pennsylvania.
RESULTS: Right ventricle:left ventricle diameter ratio (hazard ratio [HR], 4.5; 95% CI, 1.7-11.9), moderate to severe right atrial and right ventricular dilation (HR, 2.9; 95% CI, 1.4-5.9; and HR, 2.7; 95% CI, 1.4-5.4, respectively) and right ventricular dysfunction (HR, 5.5; 95% CI, 2.6-11.5) were associated with an increased risk of death. Higher pulmonary vascular resistance was also associated with increased mortality (HR per 1 Wood unit, 1.3; 95% CI, 1.1-1.5). These risk factors were independent of age, sex, race, height, weight, FVC, and lung transplantation status. Other hemodynamic indices, such as mean pulmonary artery pressure and cardiac index, were not associated with outcome.
CONCLUSIONS: Right-sided heart size and right ventricular dysfunction measured by echocardiography and higher pulmonary vascular resistance by invasive hemodynamic assessment predict mortality in patients with IPF evaluated for lung transplantation.

Entities:  

Mesh:

Year:  2013        PMID: 23450321      PMCID: PMC3734888          DOI: 10.1378/chest.12-2298

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  18 in total

1.  Pulsed Doppler tissue imaging of the velocity of tricuspid annular systolic motion; a new, rapid, and non-invasive method of evaluating right ventricular systolic function.

Authors:  J Meluzín; L Spinarová; J Bakala; J Toman; J Krejcí; P Hude; T Kára; M Soucek
Journal:  Eur Heart J       Date:  2001-02       Impact factor: 29.983

Review 2.  Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

Authors:  Vallerie V McLaughlin; Kenneth W Presberg; Ramona L Doyle; Steven H Abman; Douglas C McCrory; Terry Fortin; Gregory Ahearn
Journal:  Chest       Date:  2004-07       Impact factor: 9.410

3.  Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis.

Authors:  Christopher J Lettieri; Steven D Nathan; Scott D Barnett; Shahzad Ahmad; Andrew F Shorr
Journal:  Chest       Date:  2006-03       Impact factor: 9.410

4.  Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease.

Authors:  Selim M Arcasoy; Jason D Christie; Victor A Ferrari; Martin St John Sutton; David A Zisman; Nancy P Blumenthal; Alberto Pochettino; Robert M Kotloff
Journal:  Am J Respir Crit Care Med       Date:  2002-12-12       Impact factor: 21.405

5.  Tricuspid annular displacement predicts survival in pulmonary hypertension.

Authors:  Paul R Forfia; Micah R Fisher; Stephen C Mathai; Traci Housten-Harris; Anna R Hemnes; Barry A Borlaug; Elzbieta Chamera; Mary C Corretti; Hunter C Champion; Theodore P Abraham; Reda E Girgis; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2006-08-03       Impact factor: 21.405

Review 6.  Pulmonary hypertension in idiopathic pulmonary fibrosis.

Authors:  Nina M Patel; David J Lederer; Alain C Borczuk; Steven M Kawut
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

7.  Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis.

Authors:  Steven D Nathan; Oksana A Shlobin; Scott D Barnett; Rajeev Saggar; John A Belperio; David J Ross; Shahzad Ahmad; Rajan Saggar; Eric Libre; Joseph P Lynch; David A Zisman
Journal:  Respir Med       Date:  2008-07-10       Impact factor: 3.415

8.  Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.

Authors:  MeiLan K Han; David S Bach; Peter G Hagan; Eric Yow; Kevin R Flaherty; Galen B Toews; Kevin J Anstrom; Fernando J Martinez
Journal:  Chest       Date:  2013-06       Impact factor: 9.410

9.  BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Jürgen Behr; Kevin K Brown; Roland M du Bois; Lisa Lancaster; Joao A de Andrade; Gerd Stähler; Isabelle Leconte; Sébastien Roux; Ganesh Raghu
Journal:  Am J Respir Crit Care Med       Date:  2007-09-27       Impact factor: 21.405

10.  Assessment of pulmonary vascular resistance by Doppler echocardiography in patients with pulmonary arterial hypertension.

Authors:  Nedim Selimovic; Bengt Rundqvist; Claes-Hakan Bergh; Bert Andersson; Sofia Petersson; Lena Johansson; Odd Bech-Hanssen
Journal:  J Heart Lung Transplant       Date:  2007-09       Impact factor: 10.247

View more
  32 in total

Review 1.  Update in Pulmonary Vascular Diseases 2014.

Authors:  Elena A Goncharova; Mark T Gladwin; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2015-09-01       Impact factor: 21.405

2.  Chemokine signaling axis between endothelial and myeloid cells regulates development of pulmonary hypertension associated with pulmonary fibrosis and hypoxia.

Authors:  Aline C Oliveira; Chunhua Fu; Yuanqing Lu; Mason A Williams; Liya Pi; Mark L Brantly; Corey E Ventetuolo; Mohan K Raizada; Borna Mehrad; Edward W Scott; Andrew J Bryant
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-07-31       Impact factor: 5.464

3.  Influence of pulmonary hypertension on survival in advanced lung disease.

Authors:  Don Hayes; Sylvester M Black; Joseph D Tobias; Heidi M Mansour; Bryan A Whitson
Journal:  Lung       Date:  2015-02-18       Impact factor: 2.584

4.  Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers.

Authors:  Aaron W Trammell; Meredith E Pugh; John H Newman; Anna R Hemnes; Ivan M Robbins
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

5.  Taking it to heart: dissecting cardiopulmonary interactions in diseases of the lung and the cardiovascular system.

Authors:  Tim Lahm
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-08-12       Impact factor: 5.464

Review 6.  Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension.

Authors:  Andrea L Frump; Sébastien Bonnet; Vinicio A de Jesus Perez; Tim Lahm
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-11-02       Impact factor: 5.464

7.  Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations.

Authors:  Helen E Jo; Sharan Randhawa; Tamera J Corte; Yuben Moodley
Journal:  Drugs Aging       Date:  2016-05       Impact factor: 3.923

8.  Non-invasive screening for pulmonary hypertension in idiopathic pulmonary fibrosis.

Authors:  Laith Alkukhun; Xiao-Feng Wang; Mostafa K Ahmed; Manfred Baumgartner; Marie M Budev; Raed A Dweik; Adriano R Tonelli
Journal:  Respir Med       Date:  2016-06-02       Impact factor: 3.415

9.  Risk factors for right ventricular dysfunction in patients with lymphangioleiomyomatosis.

Authors:  Wei Hua; Wenbo Yang; Jianing Gu; Jialiang Wu; Wei Wang; Yanpu Liu; Hong Zhu; Min Zhou; Jieming Qu; Yuehua Fang
Journal:  Int J Cardiovasc Imaging       Date:  2020-09-14       Impact factor: 2.357

10.  Determinants of 6-minute walk distance in patients with idiopathic pulmonary fibrosis undergoing lung transplant evaluation.

Authors:  Mary K Porteous; Belinda N Rivera-Lebron; Maryl Kreider; James Lee; Steven M Kawut
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.